Skip to main content

Advertisement

SpringerLink
Log in

Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To retrospectively analyze the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of patients with intermediate-advanced hepatocellular carcinoma (HCC) and assess the prognostic impact of baseline characteristics.

Methods

Patients with intermediate-advanced HCC received TACE combined with sorafenib in this Phase 2 clinical trial. The primary outcome was median time to disease progression (mTTP). Secondary outcomes were median overall survival (mOS), the disease benefit rate and the sorafenib-related adverse events (AEs). Baseline characteristics’ impacts on prognosis were analyzed by univariate COX proportional hazards regression model.

Results

From June 2008 to June 2013, 75 patients were enrolled. At the end of the study, 54 patients were dead or lost to follow-up and 21 patients survived. This combination therapy resulted in a mTTP of 7.09 months (95 % CI, 1.5–45 months) and a mOS of 11.44 months (95 % CI, 1.5–45 months). The disease benefit rate was 88 %. Child-Pugh score (P = 0.000), Eastern Cooperative Oncology Group performance status (P = 0.001), Barcelona Clinic Liver Cancer stage (P = 0.000), sorafenib treatment regimen (P = 0.001), presence of extrahepatic metastasis (P = 0.002), and type of tumor (P = 0.027) were significantly correlated with OS. Multivariate analysis revealed Child-Pugh score (P = 0.001) and BCLC stage (P = 0.002) as significant independent prognostic predictors for OS. AEs were HFSR (18.7 %), gastrointestinal reactions (13.3 %), liver dysfunction (6.7 %), myelosuppression (5.3 %), fatigue (4 %), and hypertension (1.3 %).

Conclusions

TACE in combination with sorafenib might have acceptable safety and efficiency in the treatment of intermediate-advanced HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: gLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.

    Article  PubMed  CAS  Google Scholar 

  2. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2010;42(Suppl 3):S206–14. doi:10.1016/S1590-8658(10)60507-5.

    Google Scholar 

  3. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914–21. doi:10.1111/j.1572-0241.2007.01712.x.

    Article  PubMed  Google Scholar 

  4. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 2008;112(2):250–9. doi:10.1002/cncr.23175.

    Article  PubMed  CAS  Google Scholar 

  5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7.

    Article  PubMed  CAS  Google Scholar 

  6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  PubMed  CAS  Google Scholar 

  7. Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci. 2013;58(12):3389–96. doi:10.1007/s10620-013-2872-x.

    Article  PubMed  CAS  Google Scholar 

  8. Zhang YQ, Yang JY, Wang Y, Huang YH, Fan WZ, Li JP. The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma. Zhonghua yi xue za zhi. 2013;93(13):987–91.

    PubMed  Google Scholar 

  9. China TmohotPsRo. The norms of primary liver cancer diagnosis and treatment (The 2011 edition). Chin Clin Oncol. 2011;16(10):929–46.

    Google Scholar 

  10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42. doi:10.1053/jhep.2003.50047.

    Article  PubMed  CAS  Google Scholar 

  11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/j.ejca.2008.10.026.

    Article  PubMed  CAS  Google Scholar 

  12. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269(2):603–11. doi:10.1148/radiol.13130150.

    Article  PubMed  Google Scholar 

  13. Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis. 2013;14(4):181–90. doi:10.1111/1751-2980.12038.

    Article  PubMed  CAS  Google Scholar 

  14. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17(3):359–66. doi:10.1634/theoncologist.2011-0313.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54(6):2055–63. doi:10.1002/hep.24644.

    Article  PubMed  CAS  Google Scholar 

  16. Tsukui Y, Mochizuki H, Hoshino Y, Kawakami S, Kuno T, Fukasawa Y, et al. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib. Hepatogastroenterology. 2012;59(120):2536–9. doi:10.5754/hge12059.

    PubMed  CAS  Google Scholar 

  17. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2011;34(8):949–59. doi:10.1111/j.1365-2036.2011.04823.x.

    Article  PubMed  CAS  Google Scholar 

  18. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35(5):1010–21. doi:10.1053/jhep.2002.32524.

    Article  PubMed  CAS  Google Scholar 

  19. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38. doi:10.1055/s-2007-1007122.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

All the authors declare they have no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Interventional Radiology, Zhejiang Cancer Hospital, No. 38 Guangji Road, Banshanqiao, Hangzhou, 310022, China

    J. Zheng, G. Shao & J. Luo

Authors
  1. J. Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Zheng.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, J., Shao, G. & Luo, J. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. Clin Transl Oncol 16, 1012–1017 (2014). https://doi.org/10.1007/s12094-014-1189-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1189-3

Keywords

Search

Navigation